Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Relapsing-remitting Multiple Sclerosis Patients Over 8 Years: Care-MS Ii Follow-up (topaz Study)
Titel:
Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Relapsing-remitting Multiple Sclerosis Patients Over 8 Years: Care-MS Ii Follow-up (topaz Study)
Auteur:
Alroughani, R. Singer, B.A. Broadley, S. Eichau, S. Hartung, H. Havrdova, E.K. Kim, H.J. Nakamura, K. Navas, C. Pozzilli, C. Rovira, A.